PAVmed Inc. (PAVM) stock
PAVMNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$1.51−0.24 (-13.71%)
Close on Nov 17, 2026Market cap $12.07MP/E –Yield –
PAVmed EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
PAVmed's EPS for the twelve months ending Sep 30, 2024 was -$130.57. For fiscal 2025 it was -$5.63, down 137.8% from the year before. The highest annual figure on record is $14.90 in fiscal 2024.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$5.63 | -137.8% |
| FY2024 | Dec 31, 2024 | $14.90 | – |
| FY2023 | Dec 31, 2023 | -$274.80 | – |
| FY2022 | Dec 31, 2022 | -$450.90 | – |
| FY2021 | Dec 31, 2021 | -$292.50 | – |
| FY2020 | Dec 31, 2020 | -$324.00 | – |
| FY2019 | Dec 31, 2019 | -$243.00 | – |
| FY2018 | Dec 31, 2018 | -$364.50 | – |
| FY2017 | Dec 31, 2017 | -$319.50 | – |
| FY2016 | Dec 31, 2016 | -$198.00 | – |
| FY2015 | Dec 31, 2015 | -$72.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$0.87 | -108.6% |
| Q1 FY2026 | Mar 31, 2026 | -$4.42 | -110.2% |
| Q3 FY2025 | Sep 30, 2025 | -$8.70 | – |
| Q2 FY2025 | Jun 30, 2025 | -$22.08 | – |
| Q1 FY2025 | Mar 31, 2025 | $10.10 | – |
| Q3 FY2024 | Sep 30, 2024 | $43.20 | – |
| Q2 FY2024 | Jun 30, 2024 | -$35.70 | – |
| Q1 FY2024 | Mar 31, 2024 | -$78.60 | – |
| Q4 FY2023 | Dec 31, 2023 | -$59.47 | – |
| Q3 FY2023 | Sep 30, 2023 | -$71.40 | – |
| Q2 FY2023 | Jun 30, 2023 | -$63.00 | – |
| Q1 FY2023 | Mar 31, 2023 | -$83.40 | – |
| Q4 FY2022 | Dec 31, 2022 | -$99.21 | – |
| Q3 FY2022 | Sep 30, 2022 | -$130.50 | – |
| Q2 FY2022 | Jun 30, 2022 | -$130.50 | – |
| Q1 FY2022 | Mar 31, 2022 | -$88.29 | – |
| Q4 FY2021 | Dec 31, 2021 | -$110.42 | – |
| Q3 FY2021 | Sep 30, 2021 | -$67.50 | – |
| Q2 FY2021 | Jun 30, 2021 | -$63.00 | – |
| Q1 FY2021 | Mar 31, 2021 | -$58.50 | – |
| Q4 FY2020 | Dec 31, 2020 | -$74.77 | – |
| Q3 FY2020 | Sep 30, 2020 | -$49.50 | – |
| Q2 FY2020 | Jun 30, 2020 | -$54.00 | – |
| Q1 FY2020 | Mar 31, 2020 | -$148.50 | – |
| Q4 FY2019 | Dec 31, 2019 | -$85.69 | – |
| Q3 FY2019 | Sep 30, 2019 | -$45.00 | – |
| Q2 FY2019 | Jun 30, 2019 | -$58.50 | – |
| Q1 FY2019 | Mar 31, 2019 | -$58.50 | – |
| Q4 FY2018 | Dec 31, 2018 | -$116.56 | -1270.3% |
| Q3 FY2018 | Sep 30, 2018 | -$54.00 | – |
| Q2 FY2018 | Jun 30, 2018 | -$117.00 | – |
| Q1 FY2018 | Mar 31, 2018 | -$76.50 | – |
| Q4 FY2017 | Dec 31, 2017 | $9.96 | – |
| Q3 FY2017 | Sep 30, 2017 | -$171.00 | – |
| Q2 FY2017 | Jun 30, 2017 | -$36.00 | – |
| Q1 FY2017 | Mar 31, 2017 | -$144.00 | – |
| Q4 FY2016 | Dec 31, 2016 | -$58.50 | – |
| Q3 FY2016 | Sep 30, 2016 | -$63.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?